Influenza A virus vaccine H1N1 - Green Cross

Drug Profile

Influenza A virus vaccine H1N1 - Green Cross

Alternative Names: GC 1116

Latest Information Update: 10 Feb 2014

Price : $50

At a glance

  • Originator Green Cross
  • Class Influenza A virus H1N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Influenza A virus H1N1 subtype

Most Recent Events

  • 01 Jan 2014 Discontinued - Phase-III for Influenza-A virus H1N1 subtype in South Korea (IM)
  • 01 Oct 2009 Phase-III clinical trials in Influenza-A virus H1N1 subtype (prevention in adults and elderly) in South Korea (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top